Table 1.

Summary of axial spondyloarthritis patient's clinical characteristics.

Variables	AS	nr-axSpA	P
N	62	35
Age (yr; mean ± SD)	29.9 ± 9.5	30.9 ± 10.1	.65
Gender (M/F)	52/10	26/9	.25
Treatment-naïve	32 (51.61%)	15 (42.86%)	.41
Clinical features
Median disease duration (mo, P25–P75)	33.5 (5.8–62.9)	21.3 (4.1–53.8)	.87
HLA-B27 positive (n, %)	32/10 (76.19%)	24/5 (82.76%)	.51
Positive family history (n, %)	13 (21.0%)	10 (28.6%)	.40
Smoking status (n, %)	25 (40.3%)	9 (25.7%)	.15
BASDAI (median, P25–P75)	2.6 (1.0–4.4)	2.3 (1.4–4.8)	.58
BASFI (median, P25–P75)	1.1 (0.3–3.6)	1.0 (0.3–3.5)	.70
BASMI (median, P25–P75)	2.0 (1.0–5.0)	1.0 (1.0–2.0)	.00

AS = ankylosing spondylitis, BASDAI = Bath ankylosing spondylitis disease activity Index (scale 0–10), BASFI = Bath Ankylosing Spondylitis Functional Index (scale 0–10), BASMI = Bath Ankylosing Spondylitis Metrology Index (scale 0–10), HLA-B27 = human leukocyte antigen B27, nr-axSpA = non-radiographic axial spondyloarthritis, P25–P75 = percentile 25–75.